Bingchi Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bingchi Zeng has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chuting Zhang
School of Stomatology, Wenzhou Medical University, Wenzhou 325035, China
1 shared publication - Deep K. Vaishnani
School of International Studies, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China
1 shared publication - Hang Zhou
Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325000, China
1 shared publication - Huchao Mao
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
1 shared publication - Jianjian Zheng
Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
1 shared publication - Jinglu Yu
Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325000, China
1 shared publication
Latest Publications
- Open Access
- 16 June 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 900
Multi-Omics and Experimental Validation Reveal Anti-HCC Mechanisms of Tibetan Liuwei Muxiang Pill and Quercetin
Background: Hepatocellular carcinoma (HCC) remains a significant therapeutic challenge due to its complex molecular mechanisms and limited effective treatments. Although the Tibetan medicine Liuwei Muxiang Pill (LWMX) has shown efficacy in gastric and colorectal cancer, no study has yet demonstrated its potential anti-HCC activity. Objective: To evaluate the therapeutic effects of LWMX on HCC. Methods: Integrating network pharmacology, high-resolution mass spectrometry, machine learning, and molecular dynamics simulations, combined with in vitro experiments for mechanism validation. Results: The study identified (Checkpoint kinase 1) CHK1 as a key target of LWMX in HCC regulation and confirmed that quercetin can form a stable complex with CHK1. In vitro experiments demonstrated that LWMX and its active component quercetin significantly inhibit the proliferation and migration of HCC cells. Conclusions: The study establishes CHK1 as a key therapeutic target, confirming the potential of LWMX and its core component quercetin in the treatment of HCC.
- 16 June 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 900
Open AccessMulti-Omics and Experimental Validation Reveal Anti-HCC Mechanisms of Tibetan Liuwei Muxiang Pill and Quercetin
Background: Hepatocellular carcinoma (HCC) remains a significant therapeutic challenge due to its complex molecular mechanisms and limited effective treatments. Although the Tibetan medicine Liuwei Muxiang Pill (LWMX) has shown efficacy in gastric and colorectal cancer, no study has yet demonstrated its potential anti-HCC activity. Objective: To evaluate the therapeutic effects of LWMX on HCC. Methods: Integrating network pharmacology, high-resolution mass spectrometry, machine learning, and molecular dynamics simulations, combined with in vitro experiments for mechanism validation. Results: The study identified (Checkpoint kinase 1) CHK1 as a key target of LWMX in HCC regulation and confirmed that quercetin can form a stable complex with CHK1. In vitro experiments demonstrated that LWMX and its active component quercetin significantly inhibit the proliferation and migration of HCC cells. Conclusions: The study establishes CHK1 as a key therapeutic target, confirming the potential of LWMX and its core component quercetin in the treatment of HCC.